Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India
PURPOSEBiliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TOPAZ-1 trial demonstrated a 24% decrease in risk of death at 2 years with the addition of durvalumab...
Saved in:
| Main Authors: | Vamshi Krishna Muddu, Anjali Shah, Anupa John, Abhishek Raj, Ankur Bahl, Senthil J. Rajappa, Thirumalairaj Raja, Joydeep Ghosh, Viraj Lavingia, Amish Vora, Prabhat Bhargava, Anant Ramaswamy, Arif Khan, Atul Sharma, Mehak Trikha, Aditya Dhanawat, Avinash Bonda, Indraja Siripurapu, Manoj Mahajan, Nitesh Rohatgi, Mosale Venkatesha Chandrakant, Himanshu Gujarathi, Manan Vora, Sumankumar Ankathi, Vikas S. Ostwal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2024-12-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.24.00216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Jean-Charles Soria, et al.
Published: (2020-10-01) -
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
by: Mayur Patel, et al.
Published: (2025-05-01) -
Young Onset Colorectal Cancer
by: Shyam Aggarwal, et al.
Published: (2024-10-01) -
Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)
by: Purvish M. Parikh, et al.
Published: (2025-01-01) -
A pharmacovigilance analysis of post-marketing safety of durvalumab
by: An-Ju Tan, et al.
Published: (2025-05-01)